Condition
Relapsed CLL
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Active Not Recruiting1
Recruiting1
Withdrawn1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06916767Phase 1RecruitingPrimary
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
NCT03774654Phase 1Active Not Recruiting
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
NCT03639324Phase 1Withdrawn
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
NCT03091933Phase 1Unknown
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
Showing all 4 trials